The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone

被引:63
作者
Koizumi, M
Yonese, J
Fukui, I
Ogata, E
机构
[1] Canc Inst Hosp, Dept Nucl Med, Toshima Ku, Tokyo 1708455, Japan
[2] Canc Inst Hosp, Dept Urol, Tokyo 1708455, Japan
[3] Canc Inst Hosp, Dept Internal Med, Tokyo 1708455, Japan
关键词
PINP; prostate cancer; bone metastasis; prognosis;
D O I
10.1046/j.1464-410x.2001.00105.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To assess the level of a bone-formation marker, the amino-terminal propeptide of type I procollagen (PINP), for its utility in indicating bone metastasis in patients with prostate cancer. Patients and methods Several bone formation markers, i.e. PINP, the carboxy-terminal propeptide of type I procollagen (PICP), bone-specific alkaline phosphatase (BALP), and bone Gla protein (BGP), a bone resorption marker (pyridinoline cross-linked carboxy-terminal telopeptide, ICTP), and prostate specific antigen (PSA) were measured in 40 patients without and 25 patients with bone metastasis. No patient had undergone previous treatment, except for six who developed bone metastasis while undergoing hormone therapy. Results All markers except BGP were significantly higher in patients with bone metastasis than in those without. The levels of PINP correlated best with the extent of disease, although the levels of PSA, BALP and ICTP also correlated well. While PINP had the largest area under the receiver-operator characteristic curve, PSA, BALP and ICTP also produced useful curves. Conclusion The bone formation marker PINP seems to be useful for discriminating patients with and without bone metastasis. PINP may help in the early and accurate diagnosis of bone metastasis in such patients.
引用
收藏
页码:348 / 351
页数:4
相关论文
共 15 条
[1]  
CARVO MS, 1996, ENDOCR REV, V17, P333
[2]   Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma [J].
Díaz-Martín, MA ;
Traba, ML ;
de la Piedra, C ;
Guerrero, R ;
Méndez-Dávila, C ;
de la Peña, EG .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1999, 59 (02) :125-132
[3]  
HENLEY JA, 1982, RADIOLOGY, V143, P29
[4]  
Jukkola A, 1997, CANCER RES, V57, P5517
[5]   BONE METABOLIC MARKERS IN BONE METASTASES [J].
KOIZUMI, M ;
YAMADA, Y ;
TAKIGUCHI, T ;
NOMURA, E ;
FURUKAWA, M ;
KITAHARA, T ;
YAMASHITA, T ;
MAEDA, H ;
TAKAHASHI, S ;
AIBA, K ;
OGATA, E .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1995, 121 (9-10) :542-548
[6]   Dissociation of bone formation markers in bone metastasis of prostate cancer [J].
Koizumi, M ;
Maeda, H ;
Yoshimura, K ;
Yamauchi, T ;
Kawai, T ;
Ogata, E .
BRITISH JOURNAL OF CANCER, 1997, 75 (11) :1601-1604
[7]   TYPE-I COLLAGEN DEGRADATION PRODUCT (ICTP) GIVES INFORMATION ABOUT THE NATURE OF BONE METASTASES AND HAS PROGNOSTIC VALUE IN PROSTATE-CANCER [J].
KYLMALA, T ;
TAMMELA, TLJ ;
RISTELI, L ;
RISTELI, J ;
KONTTURI, M ;
ELOMAA, I .
BRITISH JOURNAL OF CANCER, 1995, 71 (05) :1061-1064
[8]   Correlation between bone metabolic markers and bone scan in prostatic cancer [J].
Maeda, H ;
Koizumi, M ;
Yoshimura, K ;
Yamauchi, T ;
Kawai, T ;
Ogata, E .
JOURNAL OF UROLOGY, 1997, 157 (02) :539-543
[9]  
OSTERLING JE, 1993, JAMA-J AM MED ASSOC, V269, P57
[10]   Collagen propeptides as indicators of collagen assembly [J].
Risteli, J ;
Niemi, S ;
Kauppila, S ;
Melkko, J ;
Risteli, L .
ACTA ORTHOPAEDICA SCANDINAVICA, 1995, 66 :183-188